Competing pursuits
V.M. studies receiving speaker honoraria and journey help from Amgen, AstraZeneca, Celgene, Roche, Tesaro, and Myelo Therapeutics. H.J.L. studies guide/advisory function with Roche, Novartis and Sanofi, and honoraria from Roche, GSK, and Sanofi. M.S. studies private charges from AstraZeneca, private charges from BioNTech, private charges from Daiichi Sankyo, private charges from Eisai, private charges from Lilly, private charges from MSD, private charges from Novartis, private charges from Pfizer, private charges from Pierre-Fabre, private charges from Roche, and private charges from Seagen exterior the submitted work; as well as, M.S. has a patent for EP 2390370 B1: A way for predicting the response of a tumor in a affected person affected by or liable to growing recurrent gynecologic most cancers in direction of a chemotherapeutic agent issued and a patent for EP 2951317 B1: A way for predicting the profit from inclusion of a taxane in a chemotherapy routine in sufferers with breast most cancers issued. A.S. obtained honoraria from Roche, Astra Zeneca, Celgene, Pfizer, Amgen, and Novartis. M.U. studies private charges for lectures and/or consultancy from Abbvie, Amgen, AstraZeneca, Daiji Sankyo, Gilead, GSK, Genzyme, Lilly, Medac, MSD Merck, Myriad Genetics, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi Aventis, Stemline, and Seagen. F.M. obtained grants and private charges from Gilead/Immunomedics, in addition to private charges from AstraZeneca, Amgen, CureVac, Celgene, Clovis Oncology, Eisai, Genomic Well being, GSK, Janssen-Cilag, Novartis, MSD, Myriad, Pfizer, PharmaMar, Pierre-Fabre, Roche, Seagen, and Tesaro. J.U.B. has obtained analysis funding from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Myriad and honoraria for lectures and participation at advisory boards from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche. C.J. has obtained analysis funding from Amgen, Roche, and Actual Sciences. He participated in Advisory Boards for AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, Lilly, Gilead, and Daiichi Sankyo. He obtained honoraria from Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead, Daichii Sankyo, and Pierre Fabre. J.H. studies grants from Novartis, Celgene and Hexal, private charges from Novartis, Lilly, Pfizer, Roche, Abbvie, AstraZeneca, Eisai, Celgene, MSD and Hexal, and journey bills from Pfizer, Roche, Daichii Sankyo and Celgene. E.S. has obtained honoraria from Pfizer, Roche, Astra, MSD, Gilead, Daiichi Sankyo, Novartis, Seagen, Lilly and Pierre Fabre. M.R. has obtained honoraria and/or consultancy payment and/or journey help from: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, and Somatex. T.L. has obtained honoraria from Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, TEVA, Tesaro, Lilly, Gilead, Daichii Sankyo and non-financial help from Roche, Pfizer, MSD, Celgene, Clovis, Daichii Sankyo, Gilead and AstraZeneca; as well as, T.L. participates at advisory boards from Tesaro, Amgen, Myriad, MSD, GSK, Novartis, Pfizer, Roche, Eisai, Lilly, Gilead, and Daichii Sankyo. W.J. studies grants and private charges from Sanofi-Aventis, Novartis, Lilly, Pfizer, Roche, Chugai, and AstraZeneca. C.D. studies grants from European Fee H2020, grants from German Most cancers Assist Translational Oncology, grants from German Breast Group, all to the establishment; private charges from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Merck, Molecular Well being, grants from Myriad and Roche to the establishment, grants from GBG basis to the establishment; as well as, C.D. has a patent on VMscope digital pathology software program with royalties paid, a patent WO2020109570A1 – most cancers immunotherapy pending, and a patent WO2015114146A1 and WO2010076322A1- remedy response issued. S.S. and J.R. declare to be GBG Forschungs GmbH worker. GBG Forschungs GmbH obtained funding for analysis grants from Abbvie, AstraZeneca, BMS, Daiichi-Sankyo, Gilead, Novartis, Pfizer, and Roche (paid to the establishment); different (non-financial/medical writing) from Daiichi-Sankyo, Gilead, Novartis, Pfizer, Roche, and Seagen (paid to the establishment). GBG Forschungs GmbH has following royalties/patents: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8 and VM Scope GmbH. S.L. declares to be GBG Forschungs GmbH worker (CEO); obtain grants from AbbVie, AstraZeneca, Celgene, Daiichi-Sankyo, Immunomedics/Gilead, Molecular Well being, Novartis, Pfizer and Roche; honoraria for Advisory board from Abbvie, Amgen, AstraZeneca, BMS, Celgene, DSI, EirGenix, Gilead, GSK, Lilly, Merck, Novartis, Olema, Pfizer, Pierre Fabre, Relay Therapeutics, Roche, Sanofi, and Seagen; honoraria as invented speaker from AstraZeneca, DSI, Gilead, Novartis, Pfizer, Roche, Seage, and Medscape. S.L. studies non-financial curiosity as advisory function in AGO Kommission Mamma, as principal investigator (Aphinity), as member in AGO, ASCO, DKG, ESMO, and different non-financial curiosity from AstraZeneca, Daiichi-Sankyo, Immunomedics/Gilead, Novartis, Pfizer, Roche, and Seagen. GBG Forschungs GmbH has the next royalties/patents: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8, and VM Scope GmbH. No different potential conflicts of curiosity related to this text have been reported.
